FInalising Remplir (CelGro Nerve) submission for FDA....still....ATI vs surgery still on track for full recruitment in 2021 and at least, we are still getting the joint J&J ATI vs Corticosteroid study results in 2021, but otherwise a pretty mediocre 4C as is clear for all to see.
Revenues unexciting. Have to wait for the guided calander 4Q Straite efforts to come through I suppose.
Still J&J ATI results remain the biggest catalyst on the horizon in 4Q 2021, but a waiting game as ever.
Ann: Appendix 4C - Quarterly, page-2
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.005(1.32%) |
Mkt cap ! $80.59M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 38.5¢ | $17.64K | 45.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 23269 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 25000 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |